• Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia
• Collaboration with Syneos Health to effectively reach the primary care market in Europe and Canada

Allschwil, Switzerland & Morrisville, N.C. – January 26, 2022
Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health^® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada.

Simon Jose, Chief Commercial Officer of Idorsia, commented:
“Daridorexant represents a significant advance in the treatment of insomnia, and it is now our job to transform and modernize insomnia treatment, notably in Europe where it would be the first dual orexin receptor antagonist available to patients. While we are building the core capabilities needed for a successful launch ourselves, the extension of our existing relationship with Syneos Health will allow us to create a best-in-class sales organization to effectively reach the primary care market in Europe and Canada. I'm sure our collective expertise will result in a growth trajectory that reflects the outstanding opportunity we see with the launch of daridorexant.”

Michelle Keefe, President, Medical Affairs & Commercial, for S…